The global mRNA synthesis raw materials market was valued at USD 1.75 billion in 2025 and is projected to reach approximately USD 3.47 billion by 2035, growing at a CAGR of 7.10%. This growth is driven by increasing demand for mRNA-based therapeutics, especially in vaccine development.

mRNA Synthesis Raw Materials Market Statical Scope

The mRNA synthesis raw materials are a list of effective fundamental raw materials, including inorganic pyrophosphatase, RNase inhibitors, linear DNA template and more. The rising genetic conditions are allowing the mass business of the market to enter niche areas with its strong command of the raw materials. The promising formulation and purification blend strengthen pharmaceutical -grade mRNA production.

The nucleotides tend to be beneficial for the market business strategy, as it's important for mRNA production. The famous personalized medicine surge is driving expansion in the market profit. While the GMP-grade raw materials are gaining traction with the therapies waiting at the late-stage clinical trials door. This builds more powerful walls for the market.

mRNA Synthesis Raw Materials Market Share, By Region, 2025 (%)

• North America – The North America regional segment dominated the market by 36% of share due to its smart concentration on nucleotides and capping agents. The smart funding for the same is strengthening the R&D sector with more precise development in the regional market.
• Europe – Europe leads by 25% of share due to the satisfying growth in the mRNA applications, featuring more demand from the rare and cancer conditions space. The new capping reagents and saRNA are an encouragement to the specialized materials introducing development in the regional market.
• Asia-Pacific – Asia Pacific's brilliance of mRNA infrastructure is bringing smart 20% of share to the attention of regional healthcare. Following this, the quality materials buckle up with more power than in the pre-pandemic stages.
• LAMEA – The LAMEA region acquires 19% of the share due to the applauding efforts of Latin America and Africa, due to their remarkable move towards local production. This on-point initiative to fulfil the requirement of locally produced raw materials is bolstering the regional market growth.

mRNA Synthesis Raw Materials Market Share, By Type, 2025 (%)

• Nucleotides – The nucleotides segment dominated the market by 38% of share, with the various nucleotide types widening the market pace. The need for mitigation of immunogenicity is drawing more attention towards the segmental market.
• Plasmid DNA – The segment acquires 12% of the share due to the fascinating purity solution to justify quality benefits. It acts as a template provider for in vitro transcription. With the extension of mRNA therapeutics, the segment stands more value in the market.
• Enzymes – The segment held 10% of the share, mainly featuring in vitro transcription. The growing demand for various infectious condition vaccines after the COVID-19 storm brings the segment worth under consideration with a high focus on the markets' ability to serve as a solution.
• Capping Agents – The capping agents segment covers 5% of the profit, as the robust technologies are in support of the segment. The ARCA, Enzymatic capping, and cleancap reagents tech-driven approaches are spurring growth and awareness in the segmental market.

mRNA Synthesis Raw Materials Market Share, By Application, 2025 (%)

• Vaccine Production – The vaccine production segment dominated the market by 84% of the share, with confidence of high purification tools and growing demand for LNPs. The modernized capping agents are a boon to the segmental growth as it serves translation efficiency and mRNA balance.
• Therapeutics Production – The segment leads covers 10% of the share, as the necessary transitions in GMP-grade raw materials are strictly subject to regulatory approval. Following this, the demand for quality raw materials in the extensive therapeutic portfolio is essential.

mRNA Synthesis Raw Materials Market Share, By End-use, 2025 (%)

• Biopharmaceutical and Pharmaceutical Companies – The biopharmaceutical and pharmaceutical companies segment dominated the market by 50% of share due to the powerful pipeline featuring a long list in the oncology field. This list assigns more assignments of high-purity materials.
• Academic and Research Institutes – The academic and research institutes carry 30% of the profit with the rising early-stage development numbers. The strong partnership between mRNA suppliers and developers with academic institutions paves the way for mature profits in the market.
• CROs and CMOs – The segment leads by 20% with the active need for customized plasmid DNA befitting the need in rare condition therapeutics and oncology. The strong portfolio of mRNA-related therapies and the rising demand for raw materials in mRNA vaccine manufacturing are stimulating growth in the segmental market.

Top Companies in the mRNA Synthesis Raw Materials Market

• F. Hoffmann-La Roche Ltd.
• Jena Bioscience GmbH
• Merck KGaA
• Yeasen Biotechnology (Shanghai) Co., Ltd.
• Thermo Fisher Scientific, Inc.
• Maravai LifeSciences
• New England Biolabs
• Creative Biogene
• HONGENE.

Segments Covered in the Report

By Type

• Capping Agents
• Nucleotides
• Plasmid DNA
• Enzymes
• Others

By Application

• Vaccine Production
• Therapeutics Production
• Others

By End Use

• Biopharmaceutical & Pharmaceutical Companies
• CROs & CMOs
• Academic & Research Institutes

By Region

• North America
• Europe
• Asia-Pacific
• LAMEA